STATs are constitutively activated in several malignancies. In primary mediastinal large B-cell lymphoma and Hodgkin lymphoma (HL), inactivating mutations in SOCS1, an inhibitor of JAK/STAT signaling, contribute to deregulated STAT activity. Based on indications that the SOCS1 mutations are caused by the B cell–specific somatic hypermutation (SHM) process, we analyzed B-cell non-HL and normal B cells for mutations in SOCS1. One-fourth of diffuse large B-cell lymphoma and follicular lymphomas carried SOCS1 mutations, which were preferentially targeted to SHM hotspot motifs and frequently obviously inactivating. Rare mutations were observed in Burkitt lymphoma, plasmacytoma, and mantle cell lymphoma but not in tumors of a non–B-cell origin. Mutations in single-sorted germinal center B cells were infrequent relative to other genes mutated as byproducts of normal SHM, indicating that SOCS1 inactivation in primary mediastinal large B-cell lymphoma, HL, diffuse large B-cell lymphoma, and follicular lymphoma is frequently the result of aberrant SHM.

STAT transcription factors are constitutively activated in several malignancies, often resulting from genomic alterations that deregulate STAT-activating kinases or interfere with termination of STAT signaling.1,2  SOCS1, whose expression is induced by activated STATs, terminates JAK/STAT signaling by binding to and marking phosphorylated JAK for proteasomal degradation.1,3  Function-impairing mutations in SOCS1 have recently been observed in primary mediastinal B-cell lymphoma (PMBL) and classic and nodular lymphocyte–predominant Hodgkin lymphoma (HL) and were associated with accumulation of several phosphorylated STATs.4-9 

Analysis of the mutation pattern of SOCS1 in nodular lymphocyte–predominant HL indicated a somatic hypermutation (SHM) origin.7  The SHM process is largely restricted to rearranged immunoglobulin V-genes in germinal center (GC) B cells.10  However, SHM occasionally also targets other genes. Rare BCL6 and FAS mutations present in GC but not naive B cells were ascribed as byproducts of “normal” SHM,11,12  whereas mutations in PIM1, c-MYC, RHOH, and PAX5, present in several B-cell lymphomas but not in normal GC B cells, were ascribed to “aberrant” SHM.12-18 

Given the indications that SOCS1 is a target of SHM, SOCS1 inactivation by SHM could, in addition to HL and PMBL, also contribute to lymphomagenesis in other GC or post-GC B cell–derived lymphomas. We thus analyzed the SOCS1 mutation status of other B-cell lymphomas, and, to clarify whether SOCS1 mutations are the result of (aberrant) SHM, also in normal GC and naive B cells, T-cell lymphomas, and solid tumors with constitutive activated STATs.

Tissue samples

Tissue samples were from the files of the Senckenberg Institute of Pathology and originally submitted for diagnostic purposes. Approval for this study was obtained from the University of Frankfurt School of Medicine Institutional Review Board. Informed consent was obtained in accordance with the Declaration of Helsinki.

Isolation of single tonsillar GC and naive B cells

Single GC and naive tonsillar B cells were sorted by fluorescence-activated cell sorter as CD20+CD38intermediateIgD and IgD+CD23+CD27CD38 cells, respectively, in 10 μL of 1× polymerase chain reaction (PCR) buffer (supplemental data, available on the Blood website; see the Supplemental Materials link at the top of the online article).

Sequence analysis of SOCS1 and V gene rearrangements

Genomic DNA was extracted from sections of frozen samples and various cell lines. DNA (10-100 ng) was used as template for amplification of the complete open reading frame of SOCS1 in a single-round PCR. PCR products were purified and directly sequenced. In cases with several mutations, genomic DNA was diluted and aliquots of various dilutions were amplified in a 2-round nested PCR. PCR products obtained from dilutions where 30% to 50% of PCRs yielded PCR products were directly sequenced. For amplification of SOCS1 from sorted single cells, cells were digested with proteinase K and a 2-round nested PCR was performed. PCR products were directly sequenced. Amplification of VH gene rearrangements to control the single-cell sort was performed as previously described19  (supplemental data).

The complete open reading frame and 60-bp untranslated region of SOCS1, all encoded by one exon, were amplified in a single PCR from genomic DNA of frozen samples of 5 types of B-cell non-Hodgkin lymphomas and directly sequenced. Mutations were detected in 7 of 26 diffuse large B-cell lymphoma (DLBCL) biopsies and 5 of 21 DLBCL cell lines, 4 of 15 follicular lymphomas (FLs) and in rare cases of Burkitt lymphoma, plasmacytoma, and mantle cell lymphoma (Table 1; supplemental Table 1). Sixteen of 19 B-cell non-Hodgkin lymphoma cases with mutations carried single, whereas 3 samples carried several mutations (Figure 1). Further analysis of these 3 samples revealed that the mutations were always on one SOCS1 allele (Figure 1).

Table 1

SOCS1 mutations in lymphomas, solid tumors, and single GC and naive B cells

Tumor or cell typeNo. of tumor samples with mutations/no. of tumor samples analyzed (%)No. of tumor samples or sequences with replacement mutationsNo. of sequences from B cells with mutations/no. of sequences from B cells analyzed*
Overall mutation frequency, percentage
5′ fragment3′ fragment
DLBCL 7/26 (27)   0.036 
DLBCL cell lines 5/21 (24)   0.034 
Follicular lymphoma 4/15 (27)   0.019 
Burkitt lymphoma 1/14 (7)   0.005 
Plasmacytoma 1/15 (6)   0.005 
Mantle cell lymphoma 1/15 (6)   0.005 
Anaplastic large cell lymphoma 0/16     
Breast cancer 0/16     
Gastrointestinal stroma tumor 0/11     
Donor 1 GC B cell  1/22 0/30 0.005 
Donor 2 GC B cell  3/25 0/25 0.015 
Donor 3 naive B cell   0/20 0/20  
Donor 3 GC B cell   0/20 0/20  
All GC B cells  4/67 0/75 0.007 
Tumor or cell typeNo. of tumor samples with mutations/no. of tumor samples analyzed (%)No. of tumor samples or sequences with replacement mutationsNo. of sequences from B cells with mutations/no. of sequences from B cells analyzed*
Overall mutation frequency, percentage
5′ fragment3′ fragment
DLBCL 7/26 (27)   0.036 
DLBCL cell lines 5/21 (24)   0.034 
Follicular lymphoma 4/15 (27)   0.019 
Burkitt lymphoma 1/14 (7)   0.005 
Plasmacytoma 1/15 (6)   0.005 
Mantle cell lymphoma 1/15 (6)   0.005 
Anaplastic large cell lymphoma 0/16     
Breast cancer 0/16     
Gastrointestinal stroma tumor 0/11     
Donor 1 GC B cell  1/22 0/30 0.005 
Donor 2 GC B cell  3/25 0/25 0.015 
Donor 3 naive B cell   0/20 0/20  
Donor 3 GC B cell   0/20 0/20  
All GC B cells  4/67 0/75 0.007 

In 4 cases of DLBCL (cases 1, 4, 5, and 6) with SOCS1 mutations, where normal tissue could be separated from the tumor by microdissection, the absence of SOCS1 mutations in the normal tissue revealed the somatic origin of the mutations in the lymphomas. All plasmacytomas were extramedullary. All anaplastic large cell lymphomas were ALK+ and the breast cancers HER2+ in immunohistochemistry. Successful sorting of naive and GC B cells by fluorescence-activated cell sorter was controlled by amplification of VH genes from 20 naive and 20 GC B cells. Whereas all GC B cells carried somatic mutations (average mutation frequency, 8.8%; range, 3.2%-22.2%), all naive B cells were unmutated. One DLBCL carried only a mutation in the 5′ untranslated region. Of the DLBCL cell lines, OCI-LY-1 carried a silent and OCI-LY-18 a mutation in the 3′ untranslated region. The mutations in the DLBCL cell lines and primary samples with replacement mutations are shown in Figure 1 and supplemental Table 1. The DLBCL cell lines OCI-LY-3, -4, -7, -8, -10, SU-DHL-4, -5, -6, -7, -10, DB, HAT, Karpas 422, Pfeiffer, Toledo, and WSU carried no SOCS1 mutations. With the exception of Farage, all mutations were detected as double sequences in sequence electropherograms.

*

Length of the 5′ fragment, 305 bp; 3′ fragment, 513 bp.

Single nucleotide missense mutations and deletions. For tumor samples, mutation frequencies were calculated assuming that 2 alleles were amplified. For sequences from B cells, mutation frequencies were calculated assuming that always 1 allele was amplified. However, in 3 of 4 cells with mutations, the mutations were detected as double peaks, indicating that, probably from a considerable fraction of cells, 2 alleles were amplified. Assuming that 2 alleles were amplified from 75% of the cells, the mutation frequency for all 3 donors together would be 0.005%.

Figure 1

SOCS1 mutations in DLBCL and FL. (Top) A scheme of the SOCS1 protein with functionally important regions.20  For DLBCL and FL primary cases and DLBCL cell lines, only replacement mutations are shown. For missense mutations, the amino acid exchanges are shown in the single letter code. In DLBCL2, a nonsense mutation, in DLBCL3 and 6, and SU-DHL-8, small out-of-frame deletions (resulting from reading frame shifts 84, 48, and 19 amino acids, respectively, unrelated to SOCS1 followed by stop codons were encoded) and in OCI-LY-19 a large deletion/insertion (encoding 14 amino acids unrelated to SOCS1 before a stop codon) caused obviously function-impairing truncations of SOCS1 protein, and the same applies to the 9- and 5-amino-acid deletions in functionally important regions in Farage and FL1. The mutations in the Farage cell line were detected as single peaks in sequence electropherograms, indicative of a lack of an unmutated allele. All other mutations in primary cases and cell lines appeared as double peaks. Thus, a second unmutated allele was always present in the 4 cell lines with double peaks. In biopsies the unmutated alleles could be the result of the presence of a second unmutated allele in the tumor cells but also originate from nontumor cells present in the lymphoma biopsies. For the 2 DLBCL samples with several mutations, dilution of the genomic DNA and subsequent 2-round PCRs to amplify single molecules revealed that in both cases all mutations were on one SOCS1 allele.

Figure 1

SOCS1 mutations in DLBCL and FL. (Top) A scheme of the SOCS1 protein with functionally important regions.20  For DLBCL and FL primary cases and DLBCL cell lines, only replacement mutations are shown. For missense mutations, the amino acid exchanges are shown in the single letter code. In DLBCL2, a nonsense mutation, in DLBCL3 and 6, and SU-DHL-8, small out-of-frame deletions (resulting from reading frame shifts 84, 48, and 19 amino acids, respectively, unrelated to SOCS1 followed by stop codons were encoded) and in OCI-LY-19 a large deletion/insertion (encoding 14 amino acids unrelated to SOCS1 before a stop codon) caused obviously function-impairing truncations of SOCS1 protein, and the same applies to the 9- and 5-amino-acid deletions in functionally important regions in Farage and FL1. The mutations in the Farage cell line were detected as single peaks in sequence electropherograms, indicative of a lack of an unmutated allele. All other mutations in primary cases and cell lines appeared as double peaks. Thus, a second unmutated allele was always present in the 4 cell lines with double peaks. In biopsies the unmutated alleles could be the result of the presence of a second unmutated allele in the tumor cells but also originate from nontumor cells present in the lymphoma biopsies. For the 2 DLBCL samples with several mutations, dilution of the genomic DNA and subsequent 2-round PCRs to amplify single molecules revealed that in both cases all mutations were on one SOCS1 allele.

Close modal

SHM preferentially targets RGYW hotspot motifs and generates single nucleotide substitutions more frequently than insertions and deletions.21  Taking DLBCLs and FLs together, hotspots were 5.4 times more frequently mutated than expected (30% of mutations in hotspots, whereas 5.6% of the amplified SOCS1 region are hotspots), and single nucleotide substitutions were much more frequent than deletions (23 vs 6). This indicates that the mutations in SOCS1 in DLBCLs and FLs are likely the result of SHM.

In 13 of 16 mutated DLBCLs and FLs, the mutations caused alterations in the SOCS1 protein, which were in 7 cases most probably function-impairing (Figure 1). Three DLBCLs carried only silent mutations or mutations in untranslated regions. The ratio of replacement to silent mutations was 3.5, only marginallly above the ratio of 3.0 for unselected mutations. It is thus probable that a considerable fraction of the SOCS1 mutations was not selected during lymphomagenesis.

To clarify whether SOCS1 is accidentally targeted by normal SHM in GC B cells, we sorted single GC and naive B cells from tonsils and amplified SOCS1 in nested 2 round PCRs in 2 overlapping fragments, which were directly sequenced. All 40 PCR fragments from naive B cells were unmutated (Table 1). Taking all GC cells together, single mutations were detected in 4 of 67 (5.9%) 5′ SOCS1 fragments and 0 of 75 3′ SOCS1 fragments, with an overall mutation frequency of 0.007%. In comparable studies, mutation frequencies in BCL6 and CD95 were 0.1% and 0.03% and significantly higher compared with naive B cells, whereas PAX5 and RHOH showed frequencies of 0.03% and 0.005%, which were comparable with naive B cells.11,12 SOCS1 is thus also compared with other accidentally mutated genes, rarely mutated in normal GC cells.

STATs are also constitutively activated in several tumors not derived from B cells, such as anaplastic large cell lymphoma, gastrointestinal stromal tumors, and breast cancer.2,22,23  SOCS1 was amplified and sequenced from several samples of these entities and was always unmutated (Table 1). Mutations in SOCS1 are thus restricted to B-cell lymphomas, in line with an SHM origin.

Taking the restriction of SOCS1 mutations to the GC-derived lymphomas PMBL, HL, DLBCL, and FL together with the SOCS1 mutation pattern, it is most probable that the mutations originate from SHM. As SOCS1 mutations were infrequent in GC B cells but frequent in HL, PMBL, DLBCL, and FL, all entities in which aberrant SHM has been observed, and as there were no indications for stringent selection of rare SOCS1 mutations occurring as byproducts of normal SHM, the SOCS1 mutations are most probably the result of aberrant SHM. The so far known targets of aberrant SHM are protooncogenes. Because of the preferential targeting of normal and aberrant SHM to the 1500 bp downstream of promoters, most mutations were in 5′ untranslated regions and introns and therefore largely without obvious functional consequences, although the aberrant SHM process may promote the occurrence of translocations.12  In the case of SOCS1, encoded by 2 exons separated by a short intron, the complete coding region is within 1500 bp downstream of the SOCS1 promoter, and mutations in the coding region thus occur at high frequencies. As most mutations in coding regions are deleterious, a large fraction will inactivate the tumor suppressor gene SOCS1 and could promote lymphomagenesis when both alleles would be inactivated. However, in all samples but one cell line, in addition to a mutated an unmutated SOCS1 allele was always present. Besides inactivating mutations and larger genomic deletions, SOCS1 can be inactivated by hypermethylation24 ; and indeed, in 2 DLBCL cell lines with SOCS1 mutations, no SOCS1 RNA expression from the unmutated alleles could be detected (supplemental data), indicating that SOCS1 hypermethylation may also occur in DLBCLs.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

The authors thank Sabine Albrecht and Ekatherini Hadzoglou for excellent technical assistance and Laura Pasqualucci and Margaret Shipp for providing us with reagents.

This work was supported by grants from the Deutsche Forschungsgemeinschaft (BR 1238/6-3) and the Deutsche Krebshilfe (107572).

Contribution: A.M. and C.R. designed and performed research and analyzed and interpreted data; M.S. and E.O. performed research and analyzed data; W.B. analyzed and interpreted data; M.-L.H. provided samples and interpreted data; R.K. designed research and analyzed and interpreted data; and A.B. designed research, analyzed and interpreted data, and drafted the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Andreas Bräuninger, Gerhard-Domagk-Institute for Pathology, University of Münster, Gerhard-Domagk-Str 17, 48149 Münster, Germany; e-mail: [email protected].

1
Haura
 
EB
Turkson
 
J
Jove
 
R
Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer.
Nat Clin Pract Oncol
2005
, vol. 
2
 
6
(pg. 
315
-
324
)
2
Yu
 
H
Jove
 
R
The STATs of cancer: new molecular targets come of age.
Nat Rev Cancer
2004
, vol. 
4
 
2
(pg. 
97
-
105
)
3
Davey
 
GM
Heath
 
WR
Starr
 
R
SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation.
Tissue Antigens
2006
, vol. 
67
 
1
(pg. 
1
-
9
)
4
Melzner
 
I
Bucur
 
AJ
Brüderlein
 
S
et al. 
Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line.
Blood
2005
, vol. 
105
 
6
(pg. 
2535
-
2542
)
5
Melzner
 
I
Weniger
 
MA
Bucur
 
AJ
et al. 
Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein.
Int J Cancer
2006
, vol. 
118
 
8
(pg. 
1941
-
1944
)
6
Mestre
 
C
Rubio-Moscardo
 
F
Rosenwald
 
A
et al. 
Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays.
Leukemia
2005
, vol. 
19
 
6
(pg. 
1082
-
1084
)
7
Mottok
 
A
Renne
 
C
Willenbrock
 
K
Hansmann
 
ML
Bräuninger
 
A
Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6.
Blood
2007
, vol. 
110
 
9
(pg. 
3387
-
3390
)
8
Weniger
 
MA
Barth
 
TF
Möller
 
P
Genomic alterations in Hodgkin's lymphoma.
Int J Hematol
2006
, vol. 
83
 
5
(pg. 
379
-
384
)
9
Weniger
 
MA
Melzner
 
I
Menz
 
CK
et al. 
Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.
Oncogene
2006
, vol. 
25
 
18
(pg. 
2679
-
2684
)
10
Küppers
 
R
Somatic hypermutation and B cell receptor selection in normal and transformed human B cells.
Ann N Y Acad Sci
2003
, vol. 
987
 (pg. 
173
-
179
)
11
Müschen
 
M
Re
 
D
Jungnickel
 
B
Diehl
 
V
Rajewsky
 
K
Küppers
 
R
Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction.
J Exp Med
2000
, vol. 
192
 
12
(pg. 
1833
-
1840
)
12
Pasqualucci
 
L
Neumeister
 
P
Goossens
 
T
et al. 
Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas.
Nature
2001
, vol. 
412
 
6844
(pg. 
341
-
346
)
13
Cerri
 
M
Capello
 
D
Muti
 
G
et al. 
Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders.
Br J Haematol
2004
, vol. 
127
 
3
(pg. 
362
-
364
)
14
Deutsch
 
AJ
Aigelsreiter
 
A
Staber
 
PB
et al. 
MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation.
Blood
2007
, vol. 
109
 
8
(pg. 
3500
-
3504
)
15
Gagyi
 
E
Balogh
 
Z
Bodor
 
C
et al. 
Somatic hypermutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression.
Haematologica
2008
, vol. 
93
 
12
(pg. 
1822
-
1828
)
16
Gaidano
 
G
Pasqualucci
 
L
Capello
 
D
et al. 
Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma.
Blood
2003
, vol. 
102
 
5
(pg. 
1833
-
1841
)
17
Liso
 
A
Capello
 
D
Marafioti
 
T
et al. 
Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma.
Blood
2006
, vol. 
108
 
3
(pg. 
1013
-
1020
)
18
Rossi
 
D
Cerri
 
M
Capello
 
D
et al. 
Aberrant somatic hypermutation in primary mediastinal large B-cell lymphoma.
Leukemia
2005
, vol. 
19
 
12
(pg. 
2363
-
2366
)
19
Bräuninger
 
A
Küppers
 
R
Spieker
 
T
et al. 
Molecular analysis of single B cells from T-cell-rich B-cell lymphoma shows the derivation of the tumor cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells.
Blood
1999
, vol. 
93
 
8
(pg. 
2679
-
2687
)
20
Kile
 
BT
Schulman
 
BA
Alexander
 
WS
Nicola
 
NA
Martin
 
HM
Hilton
 
DJ
The SOCS box: a tale of destruction and degradation.
Trends Biochem Sci
2002
, vol. 
27
 
5
(pg. 
235
-
241
)
21
Klein
 
U
Goossens
 
T
Fischer
 
M
et al. 
Somatic hypermutation in normal and transformed human B cells.
Immunol Rev
1998
, vol. 
162
 (pg. 
261
-
280
)
22
Paner
 
GP
Silberman
 
S
Hartman
 
G
Micetich
 
KC
Aranha
 
GV
Alkan
 
S
Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors.
Anticancer Res
2003
, vol. 
23
 
3B
(pg. 
2253
-
2260
)
23
Zamo
 
A
Chiarle
 
R
Piva
 
R
et al. 
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.
Oncogene
2002
, vol. 
21
 
7
(pg. 
1038
-
1047
)
24
Galm
 
O
Yoshikawa
 
H
Esteller
 
M
Osieka
 
R
Herman
 
JG
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma.
Blood
2003
, vol. 
101
 
7
(pg. 
2784
-
2788
)

Author notes

*

A.M. and C.R. contributed equally to this study.

Sign in via your Institution